1/2상모집 중

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

연구 개요

This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer immunotherapy drug also known as BNT327 and PM8002) and chemotherapy in participants with metastatic colorectal cancer (mCRC).

스폰서: 리드: 바이오엔테크
적응증: Metastatic Colorectal Cancer
중재: BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab
목표 등록: 482명
시작일: 2025-07-18
완료(예정): 2032-12-01
등록번호: NCT07079631 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.